Gupta Brinda, Gosa Barrett Laura, Liu Stephen V
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Lung Cancer (Auckl). 2024 Oct 3;15:143-148. doi: 10.2147/LCTT.S464626. eCollection 2024.
Fusions in neuregulin 1 () are rare oncogenic drivers that occur across a number of tumor types, including non-small cell lung cancer (NSCLC). has an EGF-like domain that serves as a ligand for HER3 receptors, inducing heterodimerization, usually with HER2, and subsequent activation of oncogenic downstream signaling pathways. Emerging evidence suggests that NSCLC harboring fusions do not respond as well to standard therapeutic options including chemotherapy and immunotherapy, and prognosis is poor. Novel treatment approaches targeting the HER2/HER3 pathway are under investigation. Here, we discuss the biology and detection of fusions in NSCLC and promising targeted treatment strategies for tumors harboring the mutation.
神经调节蛋白1（NRG1）融合是罕见的致癌驱动因素，存在于多种肿瘤类型中，包括非小细胞肺癌（NSCLC）。NRG1具有一个表皮生长因子（EGF）样结构域，可作为HER3受体的配体，诱导异源二聚化，通常与HER2形成异源二聚体，随后激活致癌下游信号通路。越来越多的证据表明，携带NRG1融合的NSCLC对包括化疗和免疫治疗在内的标准治疗方案反应不佳，预后较差。针对HER2/HER3途径的新型治疗方法正在研究中。在此，我们讨论NSCLC中NRG1融合的生物学特性、检测方法以及针对携带该突变肿瘤的有前景的靶向治疗策略。
